AMRI announced that the Medicines and Healthcare Regulatory Agency (MHRA) of the UK government has issued a Good Manufacturing Practice (GMP) certificate for AMRI's manufacturing facility in Holywell, Wales, UK, following an inspection in October 2011. The MHRA inspection follows a U.S. Food and Drug Administration audit of the facility in June 2011, in which no formal observations were issued. The successful completion of the US FDA and UK MHRA inspections means that AMRI's Holywell facility can now produce registered intermediates and active ingredients for use in humans and expands the range of projects that AMRI can now conduct at this facility.
AMRI Vice President, Pharmaceutical Development and Manufacturing Steven R. Hagen, Ph.D. said, "This certification completes an excellent year of regulatory cGMP audits for the Holywell facility and places it in a prime position to attract new business. The certification also closes a highly successful year of numerous audits across our global facilities that align us with best industry practices."
In 2011, AMRI's Rensselaer facility, which provides large-scale cGMP manufacturing, was inspected by FDA, in which no formal observations were issued. In addition, the Company received an approval in February 2011 from the Italian Medicines Agency (AIFA) for its Burlington, Mass. facility to manufacture a commercial drug product for a customer in the European Union.
Albany Molecular Research, Inc. announced it has signed a definitive agreement to be acquired by affiliates of The Carlyle Group and GTCR LLC for $21.75 per share in cash.
This represents a 42% premium to the 60-day weighted average closing stock price leading up to April 5, 2017 (the last ... more
AMRI announced that it has decided to close its Holywell, U.K. facility following a consultation process with employee representatives. The Holywell site provides chemical development services and small- and large scale-manufacturing services of active pharmaceutical ingredients (API) and i ... more
AMRI announced it received a 10-year federal contract award from the National Institutes of Health (NIH) for drug development and manufacturing services. This NIH/National Institute of Neurological Disorders and Stroke (NINDS) award will support NIH's Drug Manufacturing and Formulation Prog ... more
Almac announced the successful inspection of its Clinical Services operations located in Craigavon by the UK Medicines and Healthcare products Regulatory Agency (MHRA). The inspection, which occurred from 17th to 20th September 2012, was a routine inspection conducted by a MHRA inspector fr ... more
MediGene AG announced that the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) granted the authorization of the planned clinical formulation study of RhuDex®, a drug candidate being developed for the treatment of rheumatoid arthritis. The objective of the RapidFACT ... more
MediGene AG received feedback from the UK MHRA (Medicines and Healthcare products Regulatory Agency) regarding the in-vitro studies conducted with the drug candidate RhuDex(TM) for the treatment of rheumatoid arthritis. These in-vitro studies examined potential effects of RhuDex(TM) on the ... more
The Medicines and Healthcare products Regulatory Agency (MHRA) is the government agency which is responsible for ensuring that medicines and medical devices work, and are acceptably safe. The MHRA is an executive agency of the Department of Health. more